

## Special Issue

# Personalized Medicine Approaches to Depression Prevention, Diagnosis, and Therapeutics

### Message from the Guest Editor

The use of modern “omics” technologies permits more accurate medical diagnosis and tailored therapeutics. Major depressive disorder (MDD) is remarkably common, yet is often resistant to effective treatment because of its diverse presentation and complex pathogenesis, defined by both genetic and environmental factors. Recent developments on the neurobiological basis of MDD suggest that a number of novel genetic loci may be associated with MDD and related conditions. Promising work suggests that a better understanding of the risk profiles, symptom-based phenotypes, and genetics could be used to improve prevention, identification, and treatment. At the same time, depression is a profoundly human experience, and translating precision medicine approaches into effective personalized medicine must incorporate individual nuances and therapeutic relationships. This Special Issue of the *Journal of Personalized Medicine* is focused on describing the current state of personalized medicine approaches to MDD, as well as the promise of modern “omics” technologies in its prevention, detection, and treatment.

---

### Deadline for manuscript submissions

closed (20 February 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/74749](https://mdpi.com/si/74749)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).